Browse studies

Find your next paid study

220 recruiting studies matching your filters

Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small p…

Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT03739827

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Re…

Very Rare TumorsVery Rare CancersOther Solid Tumors+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07489378

Phase 1

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

Lymphodepleting ChemotherapyMyeloid Malignancies

Estimated

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06383572

Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy

Background: People who have had an allogeneic hematopoietic stem cell transplant (HCT), cellular therapy (CT), or gene therapy (GT) have bone marrow or an imm…

Cellular Immunotherapy, AdoptiveGenetic TherapyTissue Donors+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT03000244

Phase 1

A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients w…

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06015880

Observational

A Post-market Multi-center Prospective Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Breast Cancer Stages I-III.

The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer.…

AlopeciaChemotherapy-induced AlopeciaHair Loss+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Cooler Heads Care Inc.NCT05484973

Observational

Effects of Acute Cryotherapy on Musculoskeletal Function and Biomarkers for Inflammation, Oxidative Stress, and Muscle Damage

In 2020, Dubois and Esculier proposed a paradigm shift in the acute management of musculoskeletal injuries, advocating for the transition from the traditional …

Exercise Induced Muscle DamageCryotherapy

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Texas, El PasoNCT07211412

Phase 3

Pragmatic Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) (AI)

The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide wh…

Malignant Melanoma of SkinOther and Unspecified Malignant Neoplasm of SkinMelanoma in Situ+13 more

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Phase 1

A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Sm…

Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Molecular Partners AG

Phase 2

A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, predni…

B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Observational

A Randomized Pilot Study of the OSEM Oral Side-Effect Management Program in Adults Receiving Head and Neck Radiation Therapy at Premier Cancer Center

People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, an…

Head and Neck Cancer (H&N)Oral Mucositis (Ulcerative) Due to RadiationStomatitis (Oral Mucositis)+2 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

UNCANCER LLCNCT07885033

Phase 2

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse…

High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+12 more

Estimated